p-mTOR蛋白在结直肠癌组织中的表达及患者预后判断中的价值

doi:10.3969/j.issn.1004-616x.2020.03.001

Abstract

Abstract: OBJECTIVE: To investigate expression status of p-mTOR(Ser2448,an active form of mTOR)in colorectal cancer (CRC),and its correlation with clinicopathological features and prognosis. METHODS: Protein expression of p-mTOR was examined using the tissue microarrays-immunohistochemistry (TMA-IHC) technique in surgically-resected colorectal cancer tissues and adjacent normal epithelia from 441 patients. Correlations between p-mTOR expression levels,clinicopathological parameters and prognosis of patients were analyzed using the Pearson Chi-square and Fisher exact tests,and Kaplan-Meier survival and Cox regression analyses. RESULTS: Overexpression of p-mTOR was detected in 58% (254/441) of the CRC specimens but only 4% (17/441) of the normal colorectal epithelia,and the difference between them was significant (P < 0.01). In addition,elevated p-mTOR expression was positively correlated with higher pathologic T stage,lymph node metastasis,distant metastasis,and advanced clinical stage (each P < 0.05). Kaplan-Meier survival analysis showed the expression level of p-mTOR was significantly correlated with the poor prognosis of colorectal cancer patients (each P < 0.05). The disease-free survival (DFS) and overall survival (OS) of patients with high expression of p-mTOR were 52 and 60 months,respectively,which were significantly shorter than those with low expression of p-mTOR (71 and 70 months). The Cox multiple regression analyses reveal that p-mTOR overexpression was an independent prognostic factor for DFS and OS in CRC patients. CONCLUSION: p-mTOR was frequently upregulated in CRC,and its overexpression was significantly correlated with adverse outcomes;thus,it may serve as a potential prognostic marker for predicting the risk of postoperative death,recurrence and metastasis in patients with colorectal cancer.

Key words: colorectal cancer, phospho-mammalian/mechanistic target of rapamycin, prognostic biomarker, disease-free survival rate, overall survival rate

CLC Number:

R730.7

ZHU Yiqing, ZHANG Tongtong, ZHENG Junwen, HAO Jiajie, CAI Yan, WANG Mingrong, LIANG Jianwei, ZHANG Yu. Expression status of p-mTOR and its prognostic implication in colorectal cancer[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(3): 161-165.

References

[1] SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2018[J]. CA:A Cancer J Clin, 2018, 68(1):7-30.
[2] ARNOLD M, KARIM-KOS H E, COEBERGH J W, et al. Recent trends in incidence of five common cancers in 26 European countries since 1988:Analysis of the European Cancer Observatory[J]. Eur J Cancer, 2015, 51(9):1164-1187.
[3] CHEN W Q, ZHENG R S, BAADE P D, et al. Cancer statistics in China, 2015[J]. CA:A Cancer J Clin, 2016, 66(2):115-132.
[4] NITSCHE U, MAAK M, SCHUSTER T, et al. Prediction of prognosis is not improved by the seventh and latest edition of the TNM classification for colorectal cancer in a single-center collective[J]. Ann Surg, 2011, 254(5):793-801.
[5] BRENNER H, KLOOR M, POX C P. Colorectal cancer[J]. Lancet, 2014, 383(9927):1490-1502.
[6] SIEGEL R, DESANTIS C, VIRGO K, et al. Cancer treatment and survivorship statistics, 2012[J]. CA:A Cancer J Clin, 2012, 62(4):220-241.
[7] ZONCU R, EFEYAN A, SABATINI D M. mTOR:from growth signal integration to cancer, diabetes and ageing[J]. Nat Rev Mol Cell Biol, 2011, 12(1):21-35.
[8] LAPLANTE M, SABATINI D M. mTOR signaling in growth control and disease[J]. Cell, 2012, 149(2):274-293.
[9] HUANG K Z, FINGAR D C. Growing knowledge of the mTOR signaling network[J]. Semin Cell Dev Biol, 2014, 36:79-90.
[10] STICZ T, MOLNáR A, MáRK á, et al. mTOR activity and its prognostic significance in human colorectal carcinoma depending on C1 and C2 complex-related protein expression[J]. J Clin Pathol, 2017, 70(5):410-416.
[11] LI S J, WANG Z Q, HUANG J, et al. Clinicopathological and prognostic significance of mTOR and phosphorylated mTOR expression in patients with esophageal squamous cell carcinoma:a systematic review and meta-analysis[J]. BMC Cancer, 2016, 16(1):877.
[12] WIESWEG M, REIS H, KÖSTER T, et al. Phosphorylation of p70 ribosomal protein S6 kinase β-1 is an independent prognostic parameter in metastatic colorectal cancer[J]. Clin Colorectal Cancer, 2018, 17(2):e331-e352.
[13] ZHANG T T, JIANG Y Y, SHANG L, et al. Overexpression of DNAJB6 promotes colorectal cancer cell invasion through an IQGAP1/ERK-dependent signaling pathway[J]. Mol Carcinog, 2015, 54(10):1205-1213.
[14] 何华. 如何正确地对免疫组化结果进行半定量评分[J]. 中外健康文摘·临床医师, 2008, 7(5):162-163.
[15] 张彤彤, 梁建伟, 王征, 等. Cortactin蛋白在结直肠癌中的表达变化及其临床意义[J]. 癌变·畸变·突变, 2014, 26(1):20-23.
[16] MELLING N, SIMON R, IZBICKI J R, et al. Expression of phospho-mTOR kinase is abundant in colorectal cancer and associated with left-sided tumor localization[J]. Int J Clin Exp Pathol, 2015, 8(6):7009-7015.
[17] ABDEL-MAKSOUD M S, EL-GAMAL M I, BENHALILOU D R, et al. Mechanistic/mammalian target of rapamycin:Recent pathological aspects and inhibitors[J]. Med Res Rev, 2019, 39(2):631-664.
[18] RAD E, MURRAY J T, TEE A R. Oncogenic signalling through mechanistic target of rapamycin (mTOR):a driver of metabolic transformation and cancer progression[J]. Cancers (Basel), 2018, 10(1):E5.
[19] FASOLO A, SESSA C. Current and future directions in mammalian target of rapamycin inhibitors development[J]. Expert Opin Investig Drugs, 2011, 20(3):381-394.
[20] ROULIN D, CERANTOLA Y, DORMOND-MEUWLY A, et al. Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo[J]. Mol Cancer, 2010, 9:57.
[21] ZHANG Y J, DAI Q, SUN D F, et al. mTOR signaling pathway is a target for the treatment of colorectal cancer[J]. Ann Surg Oncol, 2009, 16(9):2617-2628.
[22] GULHATI P, CAI Q S, LI J, et al. Targeted inhibition of mammalian target of rapamycin signaling inhibits tumorigenesis of colorectal cancer[J]. Clin Cancer Res, 2009, 15(23):7207-7216.
[23] FUJISHITA T, AOKI K, LANE H A, et al. Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcDelta716 mice[J]. Proc Natl Acad Sci USA, 2008, 105(36):13544-13549.

Expression status of p-mTOR and its prognostic implication in colorectal cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	GAO Xiaobin, WU Xueliang, WANG Shengjie, SUN Guangyuan, WANG Wenjing, LIANG Feng, ZHAO Yifeng, LIU Zhenxian, ZHANG Yingchun. Expression of TRIM59 and its correlations with clinicopathological features in colorectal cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(6): 446-450.
[2]	LI Bo, LI Gairui, ZHAO Wei, PENG Xiaolin, ZHAO Dan, PENG Ji. Evaluation of sample preservation solution for fecal DNA detection [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 312-316.
[3]	YANG Xiuyuan, PAN Yuelong. Expression of CD10 protein in colorectal carcinomas and its clinical significance [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(5): 344-349.
[4]	MA Xiaobiao, ZHANG Qi, PAN Dingguo. Association between rs4143815 polymorphism in the B7-H1 gene and risk of colorectal cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(6): 440-443,448.
[5]	SUN Xiaonan, YUAN Qing, YANG Liyan, ZHANG Yu, CAI Yan, XU Xin, WANG Mingrong, HAO Jiajie, JIA Xuemei. FGFBP2 over-expresssion promoted cell proliferation in esophageal squamous carcinoma cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(3): 180-185,192.
[6]	LIU Tingting, LIANG Jianwei, YU Jing, CHANG Chen, HAO Jiajie, CAI Yan, ZHOU Zhixiang, WANG Mingrong, ZHANG Tongtong, ZHANG Yu. Significance in expression of KIAA1522 in colorectal cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2017, 29(2): 87-90,95.
[7]	WU Qingsong, FU Zhongxue. Association between polymorphisms of XRCC1 Arg194Trp and susceptibility to colorectal cancer in Chinese: a Meta-analysis [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2016, 28(2): 134-140.
[8]	REN Yan, QIN Wei, ZHU Qiangqiang, ZHOU Lihua, WANG Ting. VEGF expression in microcystin-LR promotion of invasion and migration in DLD-1 cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2015, 27(6): 441-445.
[9]	YAO Yujiang, XIE Ni, LIU Litao, LI Zhonghang, WAN Lili, ZHU Ting. Screening of genetic markers associated with lymph node metastasis in colorectal cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2015, 27(5): 332-340,346.
[10]	SHI Ronghui, HAN Fei, DONG Yan, ZHANG Mingqian, JIANG Xiao, YIN Li, LIU Wenbin, CAO Jia, LIU Jinyi. The expression and methylation of SOX30 gene in colorectal cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2015, 27(3): 168-171,176.
[11]	WU Lifei1, HAO Jiajie，ZHANG Tongtong，LIANG Jianwei，WANG Zheng，ZHANG Yu，XU Xin，CAI Yan，WANG Mingrong，LI Min. Expression and prognostic value of UHRF1 in colorectal cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2015, 27(1): 30-34.
[12]	CHEN Xi1;ZHANG Tong-tong;LIANG Jian-wei;SHANG Li; HUO Yan-qiu;XU Xin;ZHOU Zhi-xiang;WANG Ming-rong;ZHANG Yu;JIA Xue-mei. Analysis of PIK3CA gene mutations in Chinese colorectal cancer [J]. , 2012, 24(4): 245-248，.
[13]	ZHANG Jun1，SUN Guo-gui1，FU Zhan-zhao2，WANG Ya-di3,*，XU Hong4，GU Tao2. Expression and clinical　 significance of combined　 detection on Syk and nm23H1 proteins in colorectal cancer [J]. , 2011, 23(2): 123-127.
[14]	YANG Liu1; ZHU Ming2,△;CHEN Sen-qing2;HONG Tao3; ZHANG Yuan-ying2;MA Guo-jian2; LI Jin-tian2;ZHANG Xiao-mei2;Haruhiko Sugimura3; ZHOU Jian-nong1. Variation Analysis of the MYH Gene Associated with Sporadic Colorectal Cancer [J]. , 2009, 21(6): 435-438.
[15]	DU Yan-yan1，LIU Shi-bin2，LIU Xin1，SHAN Bao-en1. Effect of Periplocin Extracted from Cortex Periplocae on Proliferation of Colorectal Cancer Cell SW480 in Vitro and in Vivo [J]. , 2009, 21(3): 181-184.